Drug intelligence / Profile preview

pranidipine

Development stage
Phase 2
Lead developer
Taiho Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

**Pranidipine** is a long-acting, 1,4-dihydropyridine calcium channel blocker with antihypertensive activity. It acts mainly by inhibiting L-type calcium channels in vascular smooth muscle, leading to vasodilation and a reduction in blood pressure. It is classified as a third-generation dihydropyridine derivative, distinguished by a prolonged duration of action. Pranidipine can be administered once daily and has demonstrated dose-dependent blood pressure-lowering effects without clinically significant changes in heart rate. The mechanism of action is closely related to that of other dihydropyridine calcium channel blockers, targeting voltage-dependent calcium influx in vascular smooth muscle. Pranidipine may also enhance acetylcholine-induced and nitric oxide-dependent vasorelaxation by mechanisms not mediated by cyclic GMP.

Brand names
Acalas
Other names
pranidipinopranidipinum99522-79-9
02

Targets

LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on pranidipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pranidipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call